Retrospective study finds venetoclax therapies do not improve treatment outcomes in high-risk myeloid neoplasm patients, indicating complexity in clinical characteristics.
Key Points
Evaluate the clinical features and treatment outcomes of patients with DDX41-related myeloid neoplasms.
Conducted a retrospective study of DDX41-mt patients with myeloid neoplasms.
Assessed clinical and disease features to predict treatment outcomes.
Utilized germline testing and categorized patients based on mutation types.
56% composite complete remission rate in high-risk MDS and AML cases.
No significant differences in treatment outcomes between venetoclax, hypomethylating agents, and intensive chemotherapy.
The presence of concurrent somatic mutations negatively impacted overall survival.